Adrenocortical carcinoma: patterns of care and role of adjuvant radiation therapy-a population-based study and review of the literature

被引:6
作者
Atallah, S. [1 ,2 ]
Al-Assaf, H. [1 ,2 ]
Xu, Y. [1 ]
El-Sayed, S. [1 ,2 ]
机构
[1] Ottawa Hosp, Radiat Med Program, Ottawa, ON, Canada
[2] Univ Ottawa, Div Radiat Oncol, Ottawa, ON, Canada
关键词
Adrenocortical carcinoma; disease management; adjuvant therapy; radiation therapy; ADRENAL-CORTICAL CARCINOMA; SURGICAL RESECTION; PROGNOSTIC-FACTORS; MANAGEMENT; MITOTANE; CANCER; RADIOTHERAPY; SURGERY; EXPERIENCE; RECURRENCE;
D O I
10.3747/co.24.3533
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We reviewed the experience of a tertiary cancer centre in the management of adrenocortical carcinoma (ACC) treated over 40 years. We also searched the literature for guidelines related to the treatment of ACC and for evidence for adjuvant radiation therapy (RT). Methods In a retrospective chart review, ACC patients treated between January 1974 and December 2013 were identified, and patient demographics and tumour characteristics were extracted. Outcomes data, including dates and sites of failure, vital status, and cause of death, were collected. Overall survival was estimated using the Kaplan-Meier method. A MEDLINE search using PubMed, Ovid, and EMBASE was used to review the literature about the role of RT and any available management guidelines for ACC. Results Of 81 patients identified during the chart review, 39 had confirmed ACC. In 32 patients, surgical resection was performed, including in 2 patients with M1 disease. Of those 32 patients, 16 received adjuvant systemic treatment (mitotane or concurrent chemoradiation). Only 6 patients received adjuvant RT, of whom 3 are still alive (2 living with distant failure). At a median follow-up of 3.8 years, 28 patients had died (72%), 10 were living (26%), and 1 had been lost to follow-up. Of the 22 patients for whom failure data were available, 2 experienced local failure, and the rest, distant failure. Conclusions The current data are insufficient to make treatment recommendations. Use of collaborative databases and consensus about diagnostic and therapeutic guidelines are warranted for better identification of optimum management. Adjuvant RT could be a reasonable option for R1 disease, but further research is needed. Curr Oncol. 2017
引用
收藏
页码:E316 / E322
页数:7
相关论文
共 37 条
  • [1] Barzon L, 1997, ONCOLOGY, V54, P490
  • [2] Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Berruti, A.
    Baudin, E.
    Gelderblom, H.
    Haak, H. R.
    Porpiglia, F.
    Fassnacht, M.
    Pentheroudakis, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 131 - 138
  • [3] Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel
    Berruti, Alfredo
    Fassnacht, Martin
    Baudin, Eric
    Hammer, Gary
    Haak, Harm
    Leboulleux, Sophie
    Skogseid, Britt
    Allolio, Bruno
    Terzolo, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : E401 - E402
  • [4] Adrenocortical Carcinoma in the United States Treatment Utilization and Prognostic Factors
    Bilimoria, Karl Y.
    Shen, Wen T.
    Elaraj, Dina
    Bentrern, David J.
    Winchester, David J.
    Kebebew, Electron
    Sturgeon, Cord
    [J]. CANCER, 2008, 113 (11) : 3130 - 3136
  • [5] Chompret A, 2000, BRIT J CANCER, V82, P1932
  • [6] The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patients
    Crucitti, F
    Bellantone, R
    Ferrante, A
    Boscherini, M
    Crucitti, P
    Carbone, G
    Casaccia, M
    Campisi, C
    Cavallaro, A
    Sapienza, P
    DelGaudio, A
    Solidoro, G
    Dettori, G
    Marogna, P
    DiGiovanni, V
    Colli, R
    Doglietto, G
    Gozzetti, G
    Maldarizzi, F
    Marrano, D
    Minni, F
    Masenti, E
    Fronticelli, CM
    Miccoli, P
    Iacconi, P
    Mosca, F
    Roccella, M
    Mussa, A
    Sandrucci, S
    Petronio, R
    Valerio, A
    Piat, G
    Cangemi, V
    Ruberti, U
    Miani, S
    Serio, G
    Montresor, E
    Zarrilli, L
    Marzano, L
    [J]. SURGERY, 1996, 119 (02) : 161 - 170
  • [7] Adrenocortical Carcinoma
    Else, Tobias
    Kim, Alex C.
    Sabolch, Aaron
    Raymond, Victoria M.
    Kandathil, Asha
    Caoili, Elaine M.
    Jolly, Shruti
    Miller, Barbra S.
    Giordano, Thomas J.
    Hammer, Gary D.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (02) : 282 - 326
  • [8] Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma
    Else, Tobias
    Williams, Andrew R.
    Sabolch, Aaron
    Jolly, Shruti
    Miller, Barbra S.
    Hammer, Gary D.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (02) : 455 - 461
  • [9] The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma
    Erdogan, Ilknur
    Deutschbein, Timo
    Jurowich, Christian
    Kroiss, Matthias
    Ronchi, Christina
    Quinkler, Marcus
    Waldmann, Jens
    Willenberg, Holger S.
    Beuschlein, Felix
    Fottner, Christian
    Klose, Silke
    Heidemeier, Anke
    Brix, David
    Fenske, Wiebke
    Hahner, Stefanie
    Reibetanz, Joachim
    Allolio, Bruno
    Fassnacht, Martin
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (01) : 181 - 191
  • [10] Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma
    Fassnacht, Martin
    Hahner, Stefanie
    Polat, Buelent
    Koschker, Ann-Cathrin
    Kenn, Werner
    Flentje, Michael
    Allolio, Bruno
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) : 4501 - 4504